|
|
Latest Melanoma News
Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Study Evaluates Melanoma Trends in High-risk Region of United States (7/27/2010)
Melanoma incidence in Hispanic men and African-American women residing in Florida may be higher than in other regions of the United States. These findings were recently published in the journal Archives of Dermatology.
Ipilimumab Improves Outcomes in Advanced Melanoma (6/7/2010)
Among patients with previously treated, advanced melanoma, treatment with the investigational drug ipilimumab improved overall and progression-free survival. The results of this Phase III clinical trial were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
More Evidence that Indoor Tanning Increases Risk of Melanoma (6/4/2010)
Frequent indoor tanning increases the risk of developing melanoma, according to results recently published in the journal Cancer Epidemiology, Biomarkers & Prevention.
How Much Follow-up Is Appropriate for Melanoma Survivors? (6/2/2010)
Once survivors of Stage III melanoma reach a certain time period of recovery, the frequency and intensity of follow-up does not appear to be associated with discovery of resectable first relapses, according to the results of a study published early online in the Journal of Clinical Oncology.
Melanoma News By Topic
Melanoma - Screening/PreventionStudy Evaluates Melanoma Trends in High-risk Region of United States (7/27/2010)
Melanoma incidence in Hispanic men and African-American women residing in Florida may be higher than in other regions of the United States. These findings were recently published in the journal Archives of Dermatology.
More Evidence that Indoor Tanning Increases Risk of Melanoma (6/4/2010)
Frequent indoor tanning increases the risk of developing melanoma, according to results recently published in the journal Cancer Epidemiology, Biomarkers & Prevention.
May Is National Skin Cancer Awareness Month 2010 (5/3/2010)
As the month of May brings skin cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated skin cancer information throughout the year.
Indoor Tanning May Be Addictive in Some Individuals (4/29/2010)
Researchers report that some individuals may meet criteria for addiction to indoor tanning and are more likely to exhibit other addictive behaviors and affective disturbance. These results were recently published in the journal Archives of Dermatology.
More Evidence of Prevalence of Youth Tanning Bed Use (4/15/2010)
Use of tanning beds by youths age 11-17 in the UK is widespread according to results recently published in the British Medical Journal. Use of tanning beds has been linked with an increased risk of melanoma, the most deadly type of skin cancer.
Melanoma - Stages I-IIStudy Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Cancer Caregivers Devote Substantial Time and Effort (9/9/2009)
On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer.
Sentinel-node Biopsy Plays Important Role in Melanoma (9/28/2006)
According to a study published in the New England Journal of Medicine, sentinel-node biopsy provides prognostic information in patients with intermediate-thickness melanoma, and may lead to improved survival in patients who are found to have a positive sentinel node.
Addition of TNF-α to Melphalan Does Not Improve Outcomes in Melanoma Patients Undergoing Isolated Limb Perfusion (9/11/2006)
Among patients undergoing hyperthermic isolated limb perfusion for locally advanced melanoma, the addition of TNF-α to melphalan resulted in a higher complication rate without improving treatment response. These results were published in the Journal of Clinical Oncology.
Autoimmunity During Interferon Treatment for Melanoma Linked with Improved Survival (2/17/2006)
Among patients receiving immunotherapy for melanoma, those who showed evidence of autoimmunity (an immune response against the body’s own tissues) survived significantly longer than those who did not. These results were published in the New England Journal of Medicine.
Melanoma - Stage IIIStudy Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Ipilimumab Improves Outcomes in Advanced Melanoma (6/7/2010)
Among patients with previously treated, advanced melanoma, treatment with the investigational drug ipilimumab improved overall and progression-free survival. The results of this Phase III clinical trial were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
How Much Follow-up Is Appropriate for Melanoma Survivors? (6/2/2010)
Once survivors of Stage III melanoma reach a certain time period of recovery, the frequency and intensity of follow-up does not appear to be associated with discovery of resectable first relapses, according to the results of a study published early online in the Journal of Clinical Oncology.
Adjuvant Radiation Therapy May Improve Melanoma Outcomes (9/18/2009)
Adjuvant radiation therapy improves local control of melanoma following therapeutic lymph node dissection for lymph node-metastatic disease and may improve disease-specific survival, according to the results of a study published in Cancer.
Pegylated Interferon Alfa-2b Reduces Quality of Life in Stage III Melanoma (7/29/2009)
Although it improves recurrence-free survival, adjuvant (post-surgery) treatment with pegylated interferon alfa-2b adversely affects quality of life among patients with Stage III melanoma. These results were published in the Journal of Clinical Oncology.
Melanoma - Stage IVIpilimumab Improves Outcomes in Advanced Melanoma (6/7/2010)
Among patients with previously treated, advanced melanoma, treatment with the investigational drug ipilimumab improved overall and progression-free survival. The results of this Phase III clinical trial were presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Delcath PHP System Effective Against Liver Metastases (4/22/2010)
Among patients with melanoma that has metastasized (spread) to the liver, the Delcath PHP System™ appears to provide effective treatment to the liver. Full results from a Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Metastatic Melanoma Patients Undergoing Treatment with Dacarbazine and Interferon May Benefit from the Addition of Thymosin α 1 (4/15/2010)
The addition of thymosin Metastatic Melanoma Patients Undergoing Treatment with Dacarbazine and Interferon May Benefit from the Addition of Thymosin α 1 (Tα1) to dacarbazine and interferon improved overall survival and progression-free survival compared with dacarbazine and interferon alone in patients with metastatic melanoma. These results were recently published in the Journal of Clinical Oncology.
Some Patients with Previously Treated Melanoma Respond to Ipilimumab (12/22/2009)
In a Phase II clinical trial, 11% of patients with previously treated, advanced melanoma experienced a complete or partial disappearance of detectable cancer following treatment with ipilimumab at a dose of 10 mg/kg. These results were published in Lancet Oncology.
Sterotactic Radiosurgery Alone Is Preferred Treatment for Newly Diagnosed Brain Metastases (12/9/2009)
Patients with newly diagnosed brain metastases who undergo sterotactic radiosurgery plus whole-brain radiation therapy experience significant memory loss; therefore, stereotactic radiosurgery alone is the preferred method of treatment for these patients, according to the results of a study published in the Lancet Oncology.
Melanoma - RecurrentMetastatic Melanoma Patients Undergoing Treatment with Dacarbazine and Interferon May Benefit from the Addition of Thymosin α 1 (4/15/2010)
The addition of thymosin Metastatic Melanoma Patients Undergoing Treatment with Dacarbazine and Interferon May Benefit from the Addition of Thymosin α 1 (Tα1) to dacarbazine and interferon improved overall survival and progression-free survival compared with dacarbazine and interferon alone in patients with metastatic melanoma. These results were recently published in the Journal of Clinical Oncology.
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates (8/20/2008)
Patients who undergo preventive dental care prior to receiving therapy with bisphosphonates have a significantly reduced risk of developing osteonecrosis of the jaw. These results were published in an early online publication in the Annals of Oncology.
Addition of Gliadel® Wafer to Surgery and Radiation Effective for Brain Metastasis (6/22/2007)
According to an article in Clinical Cancer Research, the addition of Gliadel® Wafer (carmustine polymer wafer) to surgery plus external beam radiotherapy for the treatment of a single brain metastasis is a safe and effective regimen for patients.
Engineered Immune Cells May Help Fight Melanoma (9/1/2006)
According to an early online publication in the journal Science, a patient’s own genetically engineered immune cells may help to fight melanoma.
Therapy Involving Patient’s Immune Cells Effective for Refractory, Advanced Melanoma (4/7/2005)
According to results recently published in the Journal of Clinical Oncology, therapy involving a patient’s own immune cells appears promising in the treatment of advanced melanoma that has stopped responding to standard therapies.
|
|
